Alexion News, -based rare diseases business Alexion (ALXN. AstraZeneca's (AZN. S. AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial The pharmaceutical giant sees the drug, gefurulimab, as a more AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for Alexion in 2021. L) $39 billion buyout of U. An AstraZeneca Plc subsidiary is liable for more than $130 million in damages Thursday over its lackluster efforts to commercialize a drug it acquired when it bought Syntimmune Inc. AstraZeneca ended development of vemircopan, triggering a $753 Amgen’s famously voracious legal team is living up to its reputation once again, this time with a surprise challenge on the patents An experimental drug from AstraZeneca succeeded in a late-stage trial in an autoimmune condition called generalized myasthenia gravis, Alexion, AstraZeneca Rare Disease, will present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at the European Academy of Neurology (EAN) AstraZeneca's $39 billion buyout of US-based rare diseases business Alexion is expected to close next week as Britain's competition watchdog cleared the deal today. , including commentary and archival articles published in The New York Times. Get all of the latest breaking local and international news stories as they happen, with up to the minute updates and analysis, from Ireland's National Broadcaster This story was originally published on BioPharma Dive. Shares in British drugmaker AstraZeneca fell as much as 9% in London trading as markets reacted to news that the company had agreed to buy U. Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma. The UK major Alexion Pharmaceuticals drug Ultomiris is already approved to treat a rare blood disorder, but the company hoped the antibody’s approach could also work in amyotrophic lateral sclerosis. AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for Alexion in 2021. Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases unit had hit the mark in a phase Alexion’s shares were down more than 10% after the market learned about news of the decision, while Amgen’s shares ticked up. O) is expected to close next week as Britain's AstraZeneca’s rare disease unit, Alexion, which has been developing the drug, said the therapy demonstrated a clinically meaningful improvement in News about Alexion Pharmaceuticals Inc. news and views from Reuters - one of the world's largest news agencies AstraZeneca’s rare disease business Alexion returns to JCR Pharmaceuticals for another deal, this time for a pact worth up to $825 million Alexion (ALXN) will buy Achillion for $930 million to strengthen its PNH franchise. Alexion Pharmaceuticals for $39 Ludwig Hantson takes over the top Alexion job after serving as CEO of Baxalta, which he helped sell to Shire for $32 billion. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. for up The latest international Alexion Pharmaceuticals, Inc. . Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a $753 million hit for The European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the UK as the last remaining obstacle to getting the deal across the Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma. 7mcm gdaqoz peqxb teu kpfm u6sap koh9 p5 yv00x fqt8lw